A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma
Latest Information Update: 21 May 2024
At a glance
- Drugs Azacitidine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 May 2024 Status changed from completed to discontinued.
- 06 Jul 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.